Humana (HUM) Q2 Revenue Rises 10%

Humana reported Q2 2025 adjusted EPS of $6.27 and GAAP revenue of $32.4 billion, both surpassing analyst estimates, with revenue up 9.8% year-over-year despite a 9.9% decline in adjusted EPS. Management subsequently raised full-year adjusted EPS and revenue guidance, signaling confidence in its core strategy, partly driven by strong performance in its CenterWell integrated care segment and a revised, less severe Medicare Advantage membership decline outlook. However, the company continues to navigate margin pressures from elevated benefit and operating costs, alongside unresolved regulatory litigation concerning Star Ratings.

Analysis

Humana's Q2 2025 results depict a company successfully navigating a strategic transition, characterized by strong top-line growth and disciplined cost management against a backdrop of significant profitability pressures. The firm reported a 9.8% year-over-year increase in GAAP revenue to $32.4 billion and an adjusted EPS of $6.27, beating analyst estimates by 5.9%. However, this earnings beat is tempered by a 9.9% year-over-year decline in adjusted EPS, driven by margin compression as evidenced by a higher benefit ratio of 89.7% and an increased operating cost ratio of 10.9%. A key positive is the performance of the CenterWell integrated care segment, which contributed roughly one-third of the quarterly earnings beat and projects strong net new patient growth. Management's confidence is underscored by its decision to raise full-year adjusted EPS guidance to approximately $17.00 and revenue guidance to at least $128 billion. This optimism persists despite an anticipated, albeit moderated, decline of up to 500,000 Medicare Advantage members, reinforcing the strategy of prioritizing profitable plans over aggregate membership. Nonetheless, significant risks remain, most notably the unresolved litigation concerning Medicare Star Ratings, which could materially impact bonus payments and revenues in 2026.

Key Decisions for Investors

• Investors should weigh the positive signal of raised full-year adjusted EPS and revenue guidance against the tangible headwinds of year-over-year margin compression and ongoing Medicare Advantage membership rationalization.
• Monitor the benefit ratio and operating cost ratio in subsequent quarters, as a stabilization or decline in these metrics would be the primary indicator that management's strategy to improve profitability is taking hold.
• The unresolved litigation over Medicare Star Ratings represents a significant binary risk for 2026 revenues, and any developments should be treated as a major catalyst for the stock's performance.
• Consider the outperformance of the CenterWell segment as a core pillar of the long-term growth thesis, as its expansion into integrated care is a key driver offsetting challenges in the traditional insurance business.